Psychedelic Drugs

Could a compound found in magic mushrooms prevent one of chemotherapy’s worst side effects? New preclinical research shows that prophylactic psilocybin protects sensory nerves from toxic cancer drugs, opening the door for upcoming clinical trials in humans.

A new study suggests that consuming psilocin directly—rather than its precursor, psilocybin—provides a similar psychedelic experience with fewer side effects. Researchers also found that taking the drug under the tongue produced emotional breakthroughs despite milder effects.

Psilocin, the active compound in magic mushrooms, promotes the rapid growth of neural connections in laboratory settings. A new study reveals how these structural changes match the effects of established psychiatric drugs like ketamine and lithium.

Two new studies suggest psychedelic compounds could help treat cocaine addiction. A human trial found psilocybin combined with therapy reduced cocaine use, while an animal study indicated that environmental support is needed to prevent long-term relapse.

German college students who tried psychedelics for the first time showed slight increases in openness over a year. However, researchers say these minor personality shifts may simply reflect broader novelty-seeking behavior rather than the drugs themselves.

A new study reveals that the psychedelic drug DMT pushes brain waves into a highly random, structureless state. This biological shift directly correlates with the intense sensation of ego dissolution, shedding light on how human consciousness is maintained.

A small study in mice reveals that administering a psychedelic compound before an immune challenge can prevent severe brain inflammation. The findings suggest these drugs might prime the nervous system to resist biological stress and disease.

A new study suggests that positive emotional states, rather than profound mystical experiences, are the primary driver of symptom relief in MDMA-assisted therapy for PTSD. The findings highlight how MDMA heals trauma differently than classic psychedelics.

Two low doses of psilocybin helped chronically stressed rats recover their ability to experience pleasure while reducing anxiety. The psychedelic compound also promoted the birth of new neurons and normalized stress hormone levels.

A compound extracted from a hallucinogenic mint plant used in traditional Mexican medicine reduces facial nerve pain in mice. The findings reveal the biological mechanism behind the plant's historic use and highlight a potential target for future pain treatments.

An unusual psychedelic found in Salvia divinorum shows promise for treating pain, addiction, and stroke in animal models. However, anxiety-inducing side effects and a fleeting duration mean modified versions may be needed for human therapies.

A new study reveals that for Israeli rave-goers using psychedelics, the party is just one phase. Extensive preparations and complex physical, emotional, and social after-effects show the experience extends well beyond the dance floor.

A new meta-analysis reveals that the psychoactive drug MDMA triggers a sustained release of the social hormone oxytocin. This biological mechanism may explain the drug's ability to enhance empathy and help patients during psychiatric therapy.

A single dose of psilocybin rapidly relieved both chronic pain and depression-like symptoms in mice. Researchers discovered the psychedelic compound works by calming hyperactive neurons in a specific brain region associated with both conditions.

A new study reveals that daily doses of psilocin mucate, a stable derivative of the psychedelic compound psilocybin, significantly reduced anxiety and stress hormones in rats. However, weekly dosing did not produce the same anti-anxiety benefits.